Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Temps réel estimé Cboe BZX Autres places de cotation 19:25:06 10/06/2024			Varia. 5j.	Varia. 1 janv.
998,6 ^USD	-0,44 %		+0,97 %	+13,75 %

05/06	Un initié de Regeneron Pharmaceuticals a vendu des actions pour une valeur de 1 115 422 $, selon un récent dépôt auprès de la SEC	MT
05/06	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	05/06
ETF de la semana: Las energías limpias vuelven a despegar	05/06
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	03/06
FibroGen To Begin Trials on Tumor Treatment After FDA OK	03/06
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	03/06
Sanofi - Dupixent recommended for EU approval by the CHMP to treat patients with COPD	03/06
ETF de la semana: Las materias primas siguen teniendo potencial	31/05
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	31/05
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	31/05
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	31/05
US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert	31/05
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.	31/05
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	31/05
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	31/05
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	31/05
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	31/05
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	31/05
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	31/05
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	30/05
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing	29/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Autres langues

Filtres